BIOMAT Database Logo BIOMAT Database Logo

Mechanism-based pharmacodynamic modeling. 1994

G Levy
Department of Pharmaceutics, School of Pharmacy, State University of New York at Buffalo 14260.

UI MeSH Term Description Entries
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D010599 Pharmacokinetics Dynamic and kinetic mechanisms of exogenous chemical DRUG LIBERATION; ABSORPTION; BIOLOGICAL TRANSPORT; TISSUE DISTRIBUTION; BIOTRANSFORMATION; elimination; and DRUG TOXICITY as a function of dosage, and rate of METABOLISM. LADMER, ADME and ADMET are abbreviations for liberation, absorption, distribution, metabolism, elimination, and toxicology. ADME,ADME-Tox,ADMET,Absorption, Distribution, Metabolism, Elimination, and Toxicology,Absorption, Distribution, Metabolism, and Elimination,Drug Kinetics,Kinetics, Drug,LADMER,Liberation, Absorption, Distribution, Metabolism, Elimination, and Response
D010600 Pharmacology The study of the origin, nature, properties, and actions of drugs and their effects on living organisms. Pharmacologies
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

G Levy
Mechanism-based pharmacodynamic modeling.
January 2012, Methods in molecular biology (Clifton, N.J.),
G Levy
Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects.
December 2007, Journal of pharmacokinetics and pharmacodynamics,
G Levy
Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers.
September 2005, Pharmaceutical research,
G Levy
Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
April 2008, Trends in pharmacological sciences,
G Levy
Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling.
January 2009, Drug metabolism and pharmacokinetics,
G Levy
Mechanism-based pharmacokinetic and pharmacodynamic modeling for bispecific antibodies: challenges and opportunities.
January 2023, Expert review of clinical pharmacology,
G Levy
Mechanism-based modeling of the pharmacodynamic interaction of alphaxalone and midazolam in rats.
November 2003, The Journal of pharmacology and experimental therapeutics,
G Levy
Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis.
January 2007, Annual review of pharmacology and toxicology,
G Levy
Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol.
June 2002, Journal of pharmacokinetics and pharmacodynamics,
G Levy
Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers.
June 2006, Anesthesiology,
Copied contents to your clipboard!